Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer
about
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsSystems biology of the microvasculatureControl of cellular motility by neuropilin-mediated physical interactionsCurrent advances in biomarkers for targeted therapy in triple-negative breast cancerClinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer.VEGF targets the tumour cell.Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study.Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Triple-negative breast cancer patients treated at MD Anderson Cancer Center in phase I trials: improved outcomes with combination chemotherapy and targeted agentsEffect of C-terminal sequence on competitive semaphorin binding to neuropilin-1Pharmacological profiling of kinase dependency in cell lines across triple-negative breast cancer subtypes.Tumor Suppressor Function of the SEMA3B Gene in Human Lung and Renal CancersDysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.Semaphorin 4D Promotes Skeletal Metastasis in Breast CancerClinical implications of molecular heterogeneity in triple negative breast cancer.Analysis of gene expression of secreted factors associated with breast cancer metastases in breast cancer subtypes.Neuropilin Functions as an Essential Cell Surface Receptor.Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy.Role of tumor microenvironment in triple-negative breast cancer and its prognostic significanceEffects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis.Semaphorin 4C Protects against Allergic Inflammation: Requirement of Regulatory CD138+ Plasma Cells.Impact of semaphorin expression on prognostic characteristics in breast cancer.
P2860
Q26822432-583B82B3-A510-4658-9CA5-978AFA8AE035Q26850123-9231A16F-5D58-4E8D-83CD-8488BF7206FDQ27027713-AA85C1E9-C74F-45F9-BD33-A8F921A5333EQ28074202-456617A8-5664-4423-93A6-6582D3CE7EDFQ33564241-068192D0-7794-4C90-8898-3E5B3DD183D6Q33573324-0B328805-E064-4592-BBBF-BA52CC808107Q33789563-689249AF-0DF8-4DC3-BD92-D91715CEADC6Q34476337-660D7324-75EB-41DD-AEFF-E72CAC68D37CQ34646376-34C24A9F-3BF2-473C-931B-21A239B8EEF2Q34842279-8E649815-BFF9-4C8C-BD32-21B706DFA154Q34978420-F6149C54-2315-4625-B64A-4D89B8DA359AQ35593032-9CE999D4-F369-4FDA-855B-1C1C26C49C4DQ35764986-EC510E1E-1C56-4CB2-81BC-CD932BA71E49Q35933921-4822B39C-4A05-465A-B965-B7849F3FC695Q36271396-B1BFEFF3-DA99-4409-AB02-027DAE455F7AQ36288549-53607D15-FF10-48E8-A43D-BEF8E955E0D6Q36443978-D4F48EE6-1E38-4B51-AA7D-DE5EDF48126DQ38647802-0498F80A-B637-466D-AD04-B8C136F4A7F8Q39000232-A69D27DC-EB09-48D1-9C03-11BCC059534EQ39449113-AD5514D2-5FFD-4619-B1CE-B2355960C135Q41742917-C3B2F2AE-E3E2-4F7F-B7CE-AA9A8B3C752BQ48034611-163376E9-1F51-44AF-9E55-2A4BBE562BCCQ55333468-CA6BD8E9-CEB2-4436-BE92-08D954137073
P2860
Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer
@en
type
label
Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer
@en
prefLabel
Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer
@en
P2860
P1433
P1476
Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer
@en
P2093
Feilim Mac Gabhann
R Joseph Bender
P2860
P304
P356
10.1371/JOURNAL.PONE.0061788
P407
P577
2013-05-08T00:00:00Z